We advised Morgan Health as lead investor on the financing

Davis Polk advised JPMC Strategic Investments I Corporation (Morgan Health) in connection with its lead investment in the Series E financing round of over $125 million of Thyme Companies, Inc. The financing also included participation from Humana, CVS Health, Foresite Capital, Concord Health Partners, Frist Cressey Ventures, Town Hall Ventures and a16z Bio + Health.

Thyme is an oncology platform company, collaborating with payers and providers to transform the experience and outcomes for individuals living with cancer. Thyme partners with health plans, employers and risk-bearing providers to assume accountability for enhanced care quality, improved health outcomes and reduced total cost of care.

Morgan Health is a division of JPMorgan Chase focused on improving the quality, affordability and equity of employer sponsored health care in the United States.

The Davis Polk capital markets team included partner Jared Fine and associates Katie M. Lanphere, Pam Shu and Kristina (Kexin) Wang. Partner Corey M. Goodman and associate Zoey Chau provided tax advice. Partner David R. Bauer and associate Daniella Martino provided intellectual property advice. The financial institutions team included Counsel Andrew S. Baer. All members of the Davis Polk team are based in the New York office.

Copy link to share post